Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BI's Equity Stake in SSP exceeds 50%
November 12, 2001
- NEW PRODUCTS NEWS IN BRIEF
November 12, 2001
- Similar Function Comparison Method for Medical Materials Proposed
November 12, 2001
- AstraZeneca to Increase Share in Japan to 1.7% at End of 2001: CE McKillop
November 12, 2001
- Terumo Licenses New APD System from Debiotech of Spain
November 12, 2001
- BUSINESS NEWS IN BRIEF
November 12, 2001
- GL for Global Drug Development Needed: JPMA Expert
November 12, 2001
- Makers Providing More Products in Small Packages: Yano Report
November 12, 2001
- Prozac, Evista to Boost Eli Lilly Japan to Enter Top 10 by 2010: President Mascarenhas
November 5, 2001
- JMA Presents Proposals for Financial Reconstruction of Health Insurance Programs
November 5, 2001
- J&J to Buy Out Kyowa Hakko's Interest in Janssen Kyowa
November 5, 2001
- PMS Is Important for Products Approved via Bridging Studies: PMDEC
November 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
November 5, 2001
- Drug Classification Table for Selection of Comparator Drugs Approved by Chuikyo
November 5, 2001
- Yutaka Pharmacy Ties Up with Drug Lion, Reaching Sales of \50 Bil.
November 5, 2001
- Reduction in Price Adjustment Zone Below 2% Is Inappropriate: Korosho Director
November 5, 2001
- Seijo to Tie Up with Yoshioka Sante to Reach Sales of \158 Bil.
November 5, 2001
- BUSINESS NEWS IN BRIEF
November 5, 2001
- Yamanouchi Aims at Consumer Products Sales of \150 Bil. in 2005
November 5, 2001
- Shionogi, GSK Reach FinalAgreement for Joint Venture
November 5, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…